Volume 22 Issue 10
Oct.  2024
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2024  >  22(10): 1700-1704
PAN Luhua, ZHU Mingli, CHEN Duoxue, TU Sheng. Correlation analysis between serum lipoprotein(a) levels and mitral annulus calcification[J]. Chinese Journal of General Practice, 2024, 22(10): 1700-1704. doi: 10.16766/j.cnki.issn.1674-4152.003715
Citation: PAN Luhua, ZHU Mingli, CHEN Duoxue, TU Sheng. Correlation analysis between serum lipoprotein(a) levels and mitral annulus calcification[J]. Chinese Journal of General Practice, 2024, 22(10): 1700-1704. doi: 10.16766/j.cnki.issn.1674-4152.003715
shu

Correlation analysis between serum lipoprotein(a) levels and mitral annulus calcification

doi: 10.16766/j.cnki.issn.1674-4152.003715

  • Department of Cardiovascular Medicine, the People ' s Hospital of Bozhou, Bozhou, Anhui 236800, China

Funds:

 KJ2020A0336

  • Received Date: 2024-01-22
    Abstract
  •   Objective  This investigation delineates the potential correlation between serum Lipoprotein(a) [Lp(a)] levels, mitral annular calcification (MAC), and associated mitral valve dysfunction.  Methods  A retrospective analysis was conducted on the clinical data of 131 patients admitted to the Department of Cardiology at People ' s Hospital of Bozhou for coronary CT angiography (CTA) from January 2022 to November 2023. Based on image analysis, patients were divided into the MAC group (62 cases) and the normal group (69 cases). Comprehensive data collection encompassed demographic information (age, gender), medical history (hypertension, diabetes), and a spectrum of biochemical parameters including high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), Apolipoprotein A, Apolipoprotein B, Serum Lipoprotein(a), Creatinine, Uric Acid, Homocysteine, and history of statin use. The basic clinical data of the two groups were compared, focusing on the differences in the occurrence of mitral stenosis and regurgitation. The study also analyzed the risk factors for MAC and the risk of MAC-related mitral valve diseases.  Results  Significant differences were observed in the levels of LDL-C and Lp(a) between the MAC and the control group (P < 0.01). Logistic regression analysis identified Lp(a) as an independent risk factor for MAC (OR=1.256, 95% CI: 1.002-1.490, P=0.008). Lp(a) levels significantly differed between the normal group and both severe MAC and mild-to-moderate MAC groups (P < 0.05). The incidence of mitral stenosis did not differ significantly between the groups [8.06% (5/62) in the MAC group vs. 1.45% (1/69) in controls, P=0.165]. However, mitral regurgitation was significantly more prevalent in the MAC group [17.74% (11/62) in the MAC group vs. 4.35% (3/69) in controls, P=0.013].  Conclusion  Elevated Lp(a) levels are significant risk factors for mitral annular calcification. The presence of MAC may increase the risk of mitral regurgitation. Monitoring and controlling Lp(a) levels in patients with MAC is crucial for preventing MAC progression and associated mitral valve diseases.

     

    • FullText(HTML)
  • loading
    • References(23)
  • [1]
    MASSON W, BARBAGELATA L, OBERTI P, et al. High lipoprotein(a) levels and mitral valve disease: a systematic review[J]. Nutr Metab Cardiovasc Dis, 2023, 33(5): 925-933. doi: 10.1016/j.numecd.2023.01.025
    [2]
    XU B, KOCYIGIT D, WANG T K M, et al. Mitral annular calcification and valvular dysfunction: multimodality imaging evaluation, grading, and management[J]. Eur Heart J Cardiovasc Imaging, 2022, 23(3): e111-e122. doi: 10.1093/ehjci/jeab185
    [3]
    KRONENBERG F, MORA S, STROES E S G, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement[J]. Eur Heart J, 2022, 43(39): 3925-3946. doi: 10.1093/eurheartj/ehac361
    [4]
    KALTOFT M, SIGVARDSEN P E, AFZAL S, et al. Elevated lipoprotein(a) in mitral and aortic valve calcification and disease: the copenhagen general population study[J]. Atherosclerosis, 2022, 349: 166-174. doi: 10.1016/j.atherosclerosis.2021.11.029
    [5]
    REYES-SOFFER G, GINSBERG H N, BERGLUND L, et al. Lipoprotein(a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the american heart association[J]. Arterioscler Thromb Vasc Biol, 2022, 42(1): e48-e60.
    [6]
    GARG P K, GUAN W, KARGER A B, et al. Lipoprotein (a) and risk for calcification of the coronary arteries, mitral valve, and thoracic aorta: the multi-ethnic study of atherosclerosis[J]. J Cardiovasc Comput Tomogr, 2021, 15(2): 154-160. doi: 10.1016/j.jcct.2020.06.002
    [7]
    WANG W J, YANG L, WANG S C, et al. An automated quantification method for the agatston coronary artery calcium score on coronary computed tomography angiography[J]. Quant Imaging Med Surg, 2022, 12(3): 1787-1799. doi: 10.21037/qims-21-775
    [8]
    EBERHARD M, SCHÖNENBERGER A L N, HINZPETER R, et al. Mitral annular calcification in the elderly-quantitative assessment[J]. J Cardiovasc Comput Tomogr, 2021, 15(2): 161-166. doi: 10.1016/j.jcct.2020.06.001
    [9]
    CHURCHILL T W, YUCEL E, DEFERM S, et al. Mitral valve dysfunction in patients with annular calcification: JACC review topic of the week[J]. J Am Coll Cardiol, 2022, 80(7): 739-751. doi: 10.1016/j.jacc.2022.05.032
    [10]
    LOH W J, CHANG X, AW T C, et al. Lipoprotein(a) as predictor of coronary artery disease and myocardial infarction in a multi-ethnic Asian population[J]. Atherosclerosis, 2022, 349: 160-165. doi: 10.1016/j.atherosclerosis.2021.11.018
    [11]
    王增武, 刘静, 李建军, 等. 中国血脂管理指南(2023年)[J]. 中国循环杂志, 2023, 38(3): 237-271.

    WANG Z W, LIU J, LI J J, et al. Chinese guidelines for lipid management (2023)[J]. Chinese Circulation Journal, 2023, 38(3): 237-271.
    [12]
    KRALER S, BLASER M C, AIKAWA E, et al. Calcific aortic valve disease: from molecular and cellular mechanisms to medical therapy[J]. Eur Heart J, 2022, 43(7): 683-697. doi: 10.1093/eurheartj/ehab757
    [13]
    SHAH N, RIAZ H, KAUL R, et al. The relationship between lipoprotein (a) mitral annular calcification andmitral stenosis in a large cohort of dyslipidemia patients[J]. J Am Coll Cardiol, 2018, 71(11): A1778. DOI: 10.1016/S0735-1097(18)32319-2.
    [14]
    OBISESAN O H, KOU M, WANG F M, et al. Lipoprotein(a) and subclinical vascular and valvular calcification on cardiac computed tomography: the atherosclerosis risk in communities study[J]. J Am Heart Assoc, 2022, 11(11): e024870. DOI: 10.1161/JAHA.121.024870.
    [15]
    冯钰婷, 盛少琴, 于晓. 不同生殖衰老状态女性血脂和脂蛋白变化分析[J]. 中华全科医学, 2023, 21(5): 784-787.

    FENG Y T, SHEGN S Q, YU X. Analysis of lipid and lipoprotein levels of women in different reproductive aging stages[J]. Chinese Journal of General Practice, 2023, 21(5): 784-787.
    [16]
    俞阅彦, 翟昌林. 血清脂蛋白a和主动脉瓣退行性变的相关性分析[J]. 现代实用医学, 2022, 34(8): 1034-1036.

    YU Y Y, ZHAI C L. Analysis of the correlation between serum lipoprotein(a) and degenerative changes of the aortic valve[J]. 现代实用医学, 2022, 34(8): 1034-1036.
    [17]
    OKURA H, NAKADA Y, NOGI M, et al. Prevalence of mitral annular calcification and its association with mitral valvular disease[J]. Echocardiography, 2021, 38(11): 1907-1912. doi: 10.1111/echo.15236
    [18]
    BERTRAND P B, MIHOS C G, YUCEL E. Mitral annular calcification and calcific mitral stenosis: therapeutic challenges and considerations[J]. Curr Treat Options Cardiovasc Med, 2019, 21(4): 19. DOI: 10.1007/s11936-019-0723-6.
    [19]
    BARASCH E, GOTTDIENER J S, TRESSEL W, et al. The associations of aortic valve sclerosis, aortic annular increased reflectivity, and mitral annular calcification with subsequent aortic stenosis in older individuals: findings from the cardiovascular health study[J]. J Am Soc Echocardiogr, 2023, 36(1): 41-49. doi: 10.1016/j.echo.2022.08.013
    [20]
    SILBIGER J J. Mitral annular calcification and calcific mitral stenosis: role of echocardiography in hemodynamic assessment and management[J]. J Am Soc Echocardiogr, 2021, 34(9): 923-931. doi: 10.1016/j.echo.2021.04.007
    [21]
    PLAKOGIANNIS R, SORBERA M, FISCHETTI B, et al. The role of antisense therapies targeting lipoprotein(a)[J]. J Cardiovasc Pharmacol, 2021, 78(1): e5-e11. doi: 10.1097/FJC.0000000000001045
    [22]
    PASCA I, DANG P, TYAGI G, et al. Survival in patients with degenerative mitral stenosis: results from a large retrospective cohort study[J]. J Am Soc Echocardiogr, 2016, 29(5): 461-469. doi: 10.1016/j.echo.2015.12.012
    [23]
    NISSEN S E, WOLSKI K, BALOG C, et al. Single ascending dose study of a short interfering RNA targeting lipoprotein(a) production in individuals with elevated plasma lipoprotein(a) levels[J]. JAMA, 2022, 327(17): 1679-1687. doi: 10.1001/jama.2022.5050
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(3)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (35) PDF downloads(2) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return